Many Diagnostics (e.g., Phenotypic Tests, Molecular Tests) Are Now Available to Detect Pathogens and Determine Antibiotic Susceptibility - Identifying Drug-Resistant Bacterial Infections.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44675) has announced the addition of Identifying Drug-Resistant Bacterial Infections: Opportunity and Activity in the Diagnostics Arena to their offering. Antibiotic drug resistance is a perpetual and growing source of medical need; however, diagnostics that can identify drug-resistant pathogens are limited in number. As bacteria develop resistance to more agents and classes of antibiotics, the need for rapid diagnostics that can provide diagnostic accuracy and help in patient management (i.e., by helping physicians administer appropriate therapy quickly) will grow urgent. Diagnostics companies should take heed Verb 1. take heed - listen and pay attention; "Listen to your father"; "We must hear the expert before we make a decision" listen, hear focus, pore, rivet, center, centre, concentrate - direct one's attention on something; "Please focus on your studies and of the significant market opportunity thus presented. Get the Answers You Need to Shape Your Strategy Antibiotic drug resistance continues to plague the community and hospital settings. Which setting is more lucrative for the uptake of diagnostics? What features are needed to penetrate these settings? Currently, most diagnostics identifying drug-resistant pathogens are designed to detect methicillin-resistant Staphylococcus aureus methicillin-resistant Staphylococcus aureus Methicillin-aminoglycoside resistant Staphylococcus aureus, MRSA An organism with multiple antibiotic resistances–eg, aminoglycosides, chloramphenicol, clindamycin, erythromycin, rifampin, tetracycline, (MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. ). Which pathogens represent future opportunities? Many diagnostics (e.g., phenotypic tests, molecular tests) are now available to detect pathogens and determine antibiotic susceptibility. Where do future opportunities lie? What challenges must be overcome? With the availability of better diagnostics for identification of resistant pathogens, treatment practices in the community and the hospital are likely to be impacted. How will the widespread use of diagnostics affect drug development and use of current drugs? Will it increase or decrease use of drugs such as daptomycin, linezolid, and tigecycline? Scope * Impact of drug resistance and role of diagnostics: overview of resistance issues in the hospital and community settings and the crucial but limited role diagnostics play. * Key antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. drug-resistant pathogens: overview of key drug-resistant pathogens in the community and hospital settings, and their drug-resistance mechanisms. * Antibacterial diagnostic technologies: a review of technologies, including phenotypic and molecular tests as well as biological markers. * Key players: valuable profiles of important companies in the antibacterial diagnostics arena, including information on their current and emerging products. * Outlook: opportunities and challenges to developing antibacterial diagnostics and the effect of new antibacterial diagnostics on the pharmaceutical industry. Content Outline: Executive Summary * Strategic Considerations * Stakeholder Implications * Impact of Drug Resistance * Role of Diagnostics in Guiding Treatment * Key Antibacterial Drug-Resistant Pathogens * Staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. * Sites of Infection * Mechanism of Resistance * Enterobacteriaceae * Sites of Infection * Mechanism of Resistance * Streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. * Sites of Infection * Mechanism of Resistance * Antibacterial Diagnostic Technologies: Status and Next Steps * Phenotypic Test Technology * Molecular Test Technology * Biological Markers * C-Reactive Protein C-Reactive Protein Definition C-reactive protein (CRP) is a protein produced by the liver and found in the blood. Purpose C-reactive protein is not normally found in the blood of healthy people. * Procalcitonin * Other Biomarkers * Select Key Players in Antibacterial Diagnostics * Accelr8 Technology * Acolyte Biomedica * AdvanDx * Becton Dickinson BD (NYSE: BDX), is a medical technology company that manufactures and sells medical devices, instrument systems and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs 27,000 people in nearly 50 countries. * BioMerieux * Cepheid * HandyLab * Roche * Outlook for Diagnostics * Point-of-Care Testing point-of-care testing Lab medicine The analysis of clinical specimens as close as possible to the Pt, including bedside, ward–unit, or 'stat' regional response labs that service specified areas–eg, the ER or ICU * Impact of Diagnostics on Drug Development * Remaining Challenges * Bibliography Tables 1. Mechanisms of Bacterial Resistance to Select Antibiotic Classes of Drugs 2. Key Outcome Parameters of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Staphylococcus au·re·us n. A bacterium that causes furunculosis, pyemia, osteomyelitis, suppuration of wounds, and food poisoning. Staphylococcus aureus Staphylococcus pyogenes (MRSA and MSSA MSSA Methicillin-Sensitive Staphylococcus Aureus MSSA Microscopy Society of Southern Africa MSSA Maryland Saltwater Sportfishermen's Association MSSA Military Selective Service Act MSSA Mid-South Sociological Association MSSA Minnesota Social Service Association ) 3. Select Existing and Emerging Bacterial Detection and Susceptibility Diagnostic Technologies 4. Select Companies and Their Diagnostic Products 5. Advantages and Disadvantages of Developing Diagnostics for Antibacterial Resistance Figures 1. Timeline of Discovery of New Classes of Antibiotics 2. Common Pathogens Implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in Hospital-Acquired Infections Hospital-Acquired Infections Definition A hospital-acquired infection is usually one that first appears three days after a patient is admitted to a hospital or other health care facility. 3. Mechanisms of Antibiotic Drug Resistance 4. Mechanisms of Transferring or Spreading Drug Resistance Companies Mentioned: * Acolyte Biomedica * AdvanDx * Axis Shield * Becton Dickinson * Binax * BioMerieux * Bio-Rad * Brahms * Cellestis * Cepheid * Chemicon * Chiron * Cubist * Don Whitley Scientific * GeneOhm Sciences * Gen-Probe * Giles Scientific * HandyLab * Johnson & Johnson * King Pharmaceuticals King Pharmaceuticals (NYSE: KG), the world's 39th largest pharmaceutical company, is based in Bristol, Tennessee.[1][2] King produces a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a * Launch * Mast * Minerva Biolabs * Nanogen * New Horizons Diagnostics * Nordic Pharma * Orion Diagnostica * Pfizer * Roche * Spectral * Wyeth * Zonda For more information visit http://www.researchandmarkets.com/reports/c44675 Source: Decision Resources |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion